What is Therini Bio?
Therini Bio operates at the intersection of vascular biology and therapeutic innovation. Based at Lilly Gateway Labs, the company is dedicated to the discovery and development of therapeutics that target fibrin, a protein central to the inflammatory processes underlying various debilitating conditions. The company's foundational technology, discovered in the laboratory of Dr. Katerina Akassoglou, PhD, at the Gladstone Institutes, UCSF, and UCSD, provides a proprietary platform for addressing unmet medical needs in neurology and vascular health. By focusing on fibrin-mediated pathology, Therini Bio is carving out a distinct market position as a leader in precision medicine, aiming to transform the standard of care for patients suffering from chronic diseases where vascular integrity is compromised.
How much funding has Therini Bio raised?
Therini Bio has raised a total of $75M across 2 funding rounds:
Series A
$36M
Series A
$39M
Series A (2023): $36M with participation from Dementia Discovery Fund, Merck & Co, SV Health Investors, and Sanofi Ventures
Series A (2025): $39M led by Sanofi Ventures, Angelini Ventures, Apollo Ventures, MRL Ventures Fund, Eli Lilly, SV Health Investors, Dolby Family Ventures, and Foundation For A Better World
Key Investors in Therini Bio
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with transformative potential in oncology, immunology, and rare diseases.
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative healthcare and life science companies, providing capital and sector expertise from early growth through scale.
Apollo Ventures
Apollo Health Ventures is a transatlantic early-stage venture capital firm focused on investing in transformative healthcare companies that address age-related diseases and aging.
What's next for Therini Bio?
With the successful closure of this major strategic investment, Therini Bio is poised to enter a pivotal phase of its corporate lifecycle. The capital will be instrumental in advancing its lead therapeutic candidates through the rigorous preclinical pipeline and preparing for future clinical trials. Strategic priorities include expanding the research team, optimizing the fibrin-targeting platform, and strengthening partnerships with academic and industry collaborators. As the company scales, the focus will remain on translating scientific breakthroughs into tangible patient outcomes, effectively navigating the complexities of drug development while maintaining its commitment to rigorous, data-driven innovation in the biopharmaceutical landscape.
See full Therini Bio company page
